A Phase 1 Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Progressive Forms of Multiple Sclerosis

Authors
Category Primary study
ConferenceACTRIMS Forum 2025
Year 2025
This article has no abstract
Epistemonikos ID: ffa0e3369795ea41547949fd422eec5a4bd18297
First added on: Jan 31, 2026